Biomarkers play an integral role in new drug development by providing valuable information to facilitate the decision-making process for new therapies. Biomarker-based stratification can be used to enrich clinical populations, reducing cost and trial duration. Drawing from years of experience as pioneers in the field of clinical biomarker science, Inotiv provides guidance to help you better understand what your data means for your program and how it can be applied to advance your therapeutic along its development pipeline.
Our scientists are experts in finding the optimum analytical strategy for biomarker detection analysis and data interpretation. Our method development and validation strategies are shaped by industry guidelines to provide you with the data needed to make informed decisions to advance your preclinical and clinical programs.
Our bioanalytical team supports your program with biomarker development and translational research from preclinical discovery through clinical development.
Inotiv has extensive experience designing preclinical and clinical biomarker strategies to support our clients’ broader clinical development objectives. Working collaboratively with you, we focus on carefully selecting biomarkers to deliver results that support your decision-making process.
Our specialized biomarker services include:
Our biomarker strategies encompass the full biological spectrum, including DNA, RNA, protein, cell, and tissue analysis, matched with proven and trusted technology platforms, including:
DNA
RNA
Protein
Cell
Tissue
Copyright © 2024 Inotiv. All Rights Reserved.